A comparison of acrivastine versus terfenadine and placebo in the treatment of chronic idiopathic urticaria. 1989

T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
Department of Dermatology and Venereology, Erasmus University Rotterdam, The Netherlands.

Patients (n = 56) with a diagnosis of chronic idiopathic urticaria were assessed in a fully randomized, double-blind, crossover study to investigate the efficacy of acrivastine at two doses (8 and 4 mg) versus 60 mg terfenadine and placebo administered three times daily. All three active preparations were found to be effective, and significantly better than placebo, in controlling the signs and symptoms of urticaria. No significant differences were found between the active preparations, although in some cases efficacy trends favoured 8 mg acrivastine and terfenadine over 4 mg acrivastine. No significant differences were noted between the active treatments and placebo with regard to reports of drowsiness.

UI MeSH Term Description Entries
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006634 Histamine H1 Antagonists Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. Antihistamines, Classical,Antihistaminics, Classical,Antihistaminics, H1,Histamine H1 Antagonist,Histamine H1 Receptor Antagonist,Histamine H1 Receptor Antagonists,Histamine H1 Receptor Blockaders,Antagonists, Histamine H1,Antagonists, Histamine H1 Receptor,Antihistamines, Sedating,Blockaders, Histamine H1 Receptor,First Generation H1 Antagonists,H1 Receptor Blockaders,Histamine H1 Blockers,Receptor Blockaders, H1,Antagonist, Histamine H1,Classical Antihistamines,Classical Antihistaminics,H1 Antagonist, Histamine,H1 Antagonists, Histamine,H1 Antihistaminics,Sedating Antihistamines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
January 1989, The Journal of international medical research,
T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
January 1989, The Journal of international medical research,
T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
January 1989, The Journal of international medical research,
T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
December 1987, International journal of dermatology,
T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
March 1988, The Journal of allergy and clinical immunology,
T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
December 1990, Annals of allergy,
T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
August 1986, Cutis,
T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
March 1984, Clinical allergy,
T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
August 1987, The British journal of clinical practice,
T van Joost, and F B Blog, and W Westerhof, and F C Jansen, and T M Starink, and M S den Boer, and J J Kuneman, and S G Harvey, and J R Gibson
December 1985, British journal of clinical pharmacology,
Copied contents to your clipboard!